Regeneron posts Q2 beat as new Eylea version outperforms

mohd izzuan

Regeneron Pharmaceuticals (NASDAQ:REGN) on Friday topped Street forecasts with its Q2 financials, thanks mainly to U.S. sales for its newly developed high-dose version of its blockbuster eye care therapy Eylea, marketed with Bayer (OTCPK:BAYZF).

The Tarrytown, New York-based pharma giant recorded $3.7B